APVONasdaqPharmaceutical PreparationsFiscal year ends December 31
Aptevo Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.60−0.02 (-1.23%)
Close on Oct 19, 2026
- Market cap
- $1.91M
- P/E (TTM)
- –
- Dividend yield
- –
Aptevo Therapeutics Inc. revenue by segment
By business segment
By product or service
| Revenue | Q4 18 | Q3 18 | Q2 18 | Q4 17 | Q3 17 | Q2 17 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Product sales | $6.38M | $5.82M | $6.83M | $2.82M | $2.51M | $3.51M | 100.0% | +126.4% |
| Collaborations | – | – | – | $0 | $3.67M | $14.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Aptevo Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.